- Home
- VSTM vs CCAP Comparison
VSTM vs CCAP Comparison
Compare VSTM & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- CCAP
- Stock Information
- Founded
- VSTM 2010
- CCAP 2015
- Country
- VSTM United States
- CCAP United States
- Employees
- VSTM N/A
- CCAP N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- CCAP Finance: Consumer Services
- Sector
- VSTM Health Care
- CCAP Finance
- Exchange
- VSTM Nasdaq
- CCAP Nasdaq
- Market Cap
- VSTM 581.6M
- CCAP 505.3M
- IPO Year
- VSTM 2012
- CCAP N/A
- Fundamental
- Price
- VSTM $10.71
- CCAP $14.29
- Analyst Decision
- VSTM Strong Buy
- CCAP Buy
- Analyst Count
- VSTM 9
- CCAP 6
- Target Price
- VSTM $13.38
- CCAP $16.50
- AVG Volume (30 Days)
- VSTM 2.8M
- CCAP 184.9K
- Earning Date
- VSTM 11-04-2025
- CCAP 11-12-2025
- Dividend Yield
- VSTM N/A
- CCAP 12.25%
- EPS Growth
- VSTM N/A
- CCAP N/A
- EPS
- VSTM N/A
- CCAP 0.97
- Revenue
- VSTM $13,379,000.00
- CCAP $172,891,000.00
- Revenue This Year
- VSTM $88.60
- CCAP N/A
- Revenue Next Year
- VSTM $416.99
- CCAP N/A
- P/E Ratio
- VSTM N/A
- CCAP $14.70
- Revenue Growth
- VSTM 33.79
- CCAP N/A
- 52 Week Low
- VSTM $3.46
- CCAP $13.03
- 52 Week High
- VSTM $11.25
- CCAP $20.19
- Technical
- Relative Strength Index (RSI)
- VSTM 65.97
- CCAP 55.39
- Support Level
- VSTM $7.29
- CCAP $13.03
- Resistance Level
- VSTM $10.45
- CCAP $13.92
- Average True Range (ATR)
- VSTM 0.68
- CCAP 0.38
- MACD
- VSTM 0.23
- CCAP 0.07
- Stochastic Oscillator
- VSTM 93.53
- CCAP 90.44
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.